CARE™ Perspectives

ASCO & CUA 2019



12 Aug 2019

Members of the CARE™ Oncology faculty attended the American Society of Clinical Oncology (ASCO 2019) annual meeting from May 31st – June 4th in Chicago, IL and the Canadian Urological Association (CUA 2019) annual meeting from June 29th – July 1st in Quebec, QC.

This comprehensive CARE™ Perspectives report section from ASCO and CUA 2019 covers content in multiple prostate cancer disease stages and includes updates on the following:

CUA 2019

  • 2019 CRPC Guidelines from the CUA

ASCO 2019

  • Enzalutamide (with or without docetaxel) for mHSPC.
  • Apalutamide as a treatment option for mCSPC.
  • Subgroup analysis of apalutamide for nmCRPC.
  • Darolutamide for nmCRPC.
  • Enzalutamide versus a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic mCRPC patients.
  • Taxanes versus AR targeting therapies in patients with poor prognosis mCRPC.